Drug Approval | February 21, 2025
Roflumilast reduces inflammation in the lungs that leads to chronic obstructive pulmonary disease (COPD)
Roflumilast Tablets had annual sales of US $248 million in the United States according to IQVIA data
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad
Subscribe To Our Newsletter & Stay Updated
